Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-tracer PET Imaging in G2-G3 GEP-NETs
NCT04804371Active, not recruiting
- Sponsor
- University Health Network
- Start
- Mar 2021
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fludeoxyglucose f 18 in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by University Health Network. Primary endpoints: Discordance in tracer uptake at 2 years and Impact to patient management at 2 years. Started Mar 2021; status: active, not recruiting.
02
Drugs
fludeoxyglucose f 18
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04804371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04804371.